Serotype distribution of remaining pneumococcal meningitis in the mature PCV10/13 period: findings from the PSERENADE project

Garcia Quesada, M. et al. (2021) Serotype distribution of remaining pneumococcal meningitis in the mature PCV10/13 period: findings from the PSERENADE project. Microorganisms, 9(4), 738. (doi: 10.3390/microorganisms9040738) (PMID:33916227) (PMCID:PMC8066874)

[img] Text
237898.pdf - Published Version
Available under License Creative Commons Attribution.



Pneumococcal conjugate vaccine (PCV) introduction has reduced pneumococcal meningitis incidence. The Pneumococcal Serotype Replacement and Distribution Estimation (PSERENADE) project described the serotype distribution of remaining pneumococcal meningitis in countries using PCV10/13 for least 5–7 years with primary series uptake above 70%. The distribution was estimated using a multinomial Dirichlet regression model, stratified by PCV product and age. In PCV10-using sites (N = 8; cases = 1141), PCV10 types caused 5% of cases <5 years of age and 15% among ≥5 years; the top serotypes were 19A, 6C, and 3, together causing 42% of cases <5 years and 37% ≥5 years. In PCV13-using sites (N = 32; cases = 4503), PCV13 types caused 14% in <5 and 26% in ≥5 years; 4% and 13%, respectively, were serotype 3. Among the top serotypes are five (15BC, 8, 12F, 10A, and 22F) included in higher-valency PCVs under evaluation. Other top serotypes (24F, 23B, and 23A) are not in any known investigational product. In countries with mature vaccination programs, the proportion of pneumococcal meningitis caused by vaccine-in-use serotypes is lower (≤26% across all ages) than pre-PCV (≥70% in children). Higher-valency PCVs under evaluation target over half of remaining pneumococcal meningitis cases, but questions remain regarding generalizability to the African meningitis belt where additional data are needed.

Item Type:Articles
Additional Information:Funding: The PSERENADE project is funded by the Bill and Melinda Gates Foundation as part of the World Health Organization Pneumococcal Vaccines Technical Coordination Project, grant number INV-010429 / OPP1189065.
Glasgow Author(s) Enlighten ID:Smith, Professor Andrew
Authors: Garcia Quesada, M., Yang, Y., Bennett, J. C., Hayford, K., Zeger, S. L., Feikin, D. R., Peterson, M. E., Cohen, A. L., Almeida, S. C.G., Ampofo, K., Ang, M., Bar-Zeev, N., Bruce, M. G., Camilli, R., Chacón, G. C., Ciruela, P., Cohen, C., Corcoran, M., Dagan, R., De Wals, P., Desmet, S., Diawara, I., Gierke, R., Guevara, M., Hammitt, L. L., Hulty, M., Ho, P.-L., Jayasinghe, S., Kleynhans, J., Kristinsson, K. G., Ladhani, S. N., McGeer, A., Mwenda, J. M., Nuorti, J. P., Oishi, K., Ricketson, L. J., Sanz, J. C., Savrasova, L., Setchanova, L. P., Smith, A., Valentiner-Branth, P., Valenzuela, M. T., van der Linden, M., van Sorge, N. M., Varon, E., Winje, B. A., Yildirim, I., Zintgraff, J., and Deloria Knoll, M.
College/School:College of Medical Veterinary and Life Sciences > School of Medicine, Dentistry & Nursing > Dental School
Journal Name:Microorganisms
ISSN (Online):2076-2607
Published Online:01 April 2021
Copyright Holders:Copyright © 2021 by the authors
First Published:First published in Microorganisms 9(4):738
Publisher Policy:Reproduced under a Creative Commons Licence

University Staff: Request a correction | Enlighten Editors: Update this record